Vijay Pande hands a16z biotech leadership to Vineeta Agarwala
The biotech and life sciences team at a16z is getting a new leader, as founding investor Vijay Pande moves into a role focused on artificial intelligence and its healthcare applications, Endpoints News...
View ArticleAgios' stock drops after disclosing new liver-related safety warning in...
Agios Pharmaceuticals on Monday saw its stock price drop by more than 24% as it disclosed that its oral candidate for the blood disorder thalassemia has been submitted to regulators worldwide for...
View ArticleBelharra Therapeutics sticks with lead programs, trims workforce by 40%
San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as...
View ArticlePerson of interest arrested in connection with UnitedHealthcare CEO killing
Authorities have arrested a person of interest in connection with the fatal shooting of UnitedHealthcare CEO Brian Thompson. The arrest came after a days-long manhunt for the person who gunned down...
View ArticleSupreme Court won't take up PhRMA-Arkansas 340B expansion case
The US Supreme Court on Monday said it won't hear a case related to the expansion of the federal 340B drug discount program that pitted the industry group PhRMA against the ...
View ArticleTrump elevates disproven vaccines-autism link in interview
In his first major interview since securing another term in the White House, President-elect Donald Trump reiterated concerns with the disproven link between childhood vaccines and autism, a nod to the...
View ArticleRelation and GSK to collaborate on fibrosis, osteoarthritis
Machine learning and AI have sparked a transformation in drug discovery, but cracking the biology is still paramount. That's the thinking behind a new collaboration between UK startup Relation...
View Article#ASH24: Retrospective analysis shows potential for GLP-1s to treat blood clots
SAN DIEGO — As researchers explore more potential benefits of GLP-1 medicines, a new retrospective study is suggesting the drug class’ potential to treat venous thromboembolisms, or blood clots in the...
View Article#ASH24: Kura Oncology details 'aggressive' approach in first-line AML
SAN DIEGO — As Kura Oncology awaits key pivotal data in relapsed or refractory acute myeloid leukemia, the company is going all in on combinations in the frontline setting. On Monday, Kura and its...
View Article#ASH24: Arcellx and Gilead seek to unseat J&J-Legend in multiple myeloma
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson & Johnson. New results from a...
View Article#ASH24: BTK drugs from AstraZeneca, Lilly and BeiGene take center stage in CLL
SAN DIEGO — Some of the biggest names in BTK inhibitors presented updated datasets at the American Society of Hematology annual meeting this weekend, most notably AstraZeneca and Eli Lilly. AstraZeneca...
View ArticleNew oncology biotech launches with $52M in its pocket
A small molecule cancer biotech broke cover on Tuesday with a $52 million Series A to take on a "unique lipidation pocket" and get into the clinic around May of next year. Boston-based Tasca...
View Article#SABCS24: Olema makes case for its oral SERD with fresh data cut from Phase...
Olema Oncology unveiled new data from a Phase 1b/2 breast cancer trial on Tuesday, as it strives to catch up with other companies with oral selective estrogen receptor degraders (SERDs). Olema’s vision...
View ArticleBioNTech reports Phase 1b/2 survival data for VEGF bispecific in breast cancer
Last month, BioNTech went all-in on VEGF bispecific antibodies. On Tuesday, to validate its bet, the company shared early survival data from a mid-stage trial in an aggressive form of breast cancer ...
View ArticleRoche initially didn't want to buy Poseida — and partner Astellas didn't...
Well before Roche said it would buy out its CAR-T partner Poseida Therapeutics for $1 billion upfront, another undisclosed pharma company had sent the cell and gene therapy maker an unsolicited...
View ArticleCervoMed’s Phase 2 miss; NICE to cover Santhera’s Duchenne drug
Plus, news about Lava Therapeutics, Recursion and Aqemia: CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a...
View Article#SABCS24: Early data suggest Arvinas, Pfizer could combine their breast...
Pfizer and its partner Arvinas may have landed on a CDK4/6 inhibitor to use in combination with their oral estrogen receptor degrader in breast cancer. Interim data argue for combining vepdegestrant...
View ArticleHalia Therapeutics takes NLRP3 inhibitor into final stage of Phase 2 trial
Halia Therapeutics is moving its lead asset into the second part of a mid-stage trial following initial positive data in patients with an early form of blood cancer that affects the bone marrow. The...
View ArticleCardiff unveils positive Phase 2 data for colorectal cancer drug, $40M offering
Cardiff Oncology announced an oversubscribed $40 million offering on Tuesday after it released positive data from a mid-stage trial investigating its onvansertib combo in patients with first-line...
View Article#ASH24: J&J, Legend’s Carvykti clears a type of blood cancer in ‘nine out of...
Johnson & Johnson and Legend Biotech say their CAR-T therapy Carvykti has the potential to remove all traces of disease from certain blood cancer patients based on the latest results of a Phase 3...
View Article